{'fraction_non_alphanumeric': 0.024390243902439025, 'fraction_numerical': 0.019308943089430895, 'mean_word_length': 5.437908496732026, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Enzyme Immunoassay for ErythrocyteAldose Reductase

This two-site immunoassay measures erythrocyte aldose reductase by using monoclonal and polycional antibodies to recombinant human enzyme. Total incubation time is 2.5 h, and the limit of detection is <0.05 g/L Analytical recovery tested with blood samples from healthy and diabetic individuals was 101-106%. Average CVs within and between assays were 3.7% and 4.8%, respectively. The enzyme content determined by this system correlated well with the activity of alciosereductase isolated from the same erythrocyte preparations. The amount of erythrocyte aldose reductase per milligram of hemoglobin was higher in women than in men (P <0.001), but no significant correlation was observed between the amount of enzyme and the age of the individuals.This assay method should provide useful clinical information to optimize administration of aldose reductase inhibitors for effective prevention and treatment of diabetic complications.